LONDON—In the latest of a string of drug-development setbacks, GlaxoSmithKline PLC on Tuesday stopped a late-stage trial of its cancer vaccine after disappointing results. . The U.K. drug company had said last month that its immunotherapy treatment didn't boost survival rates among patients with non-small-cell lung cancer, a prevalent form of the disease. . ...
  